Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of PF-07275315 and PF-07264660 in adults with moderate-to-severe atopic dermatitis
CTR20242718Phase 2Active
- Sponsor
- Pfizer
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tilrekimig, ompekimig in atopic dermatitis (AD), sponsored by Pfizer. Started Jan 2025; status: active.
02
Drugs
tilrekimigompekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20242718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242718.